- Home
- XCUR vs MRSN Comparison
XCUR vs MRSN Comparison
Compare XCUR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCUR
- MRSN
- Stock Information
- Founded
- XCUR 2011
- MRSN 2001
- Country
- XCUR United States
- MRSN United States
- Employees
- XCUR N/A
- MRSN N/A
- Industry
- XCUR Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- XCUR Health Care
- MRSN Health Care
- Exchange
- XCUR Nasdaq
- MRSN Nasdaq
- Market Cap
- XCUR 32.4M
- MRSN 37.0M
- IPO Year
- XCUR N/A
- MRSN 2017
- Fundamental
- Price
- XCUR $4.23
- MRSN $8.07
- Analyst Decision
- XCUR
- MRSN Strong Buy
- Analyst Count
- XCUR 0
- MRSN 3
- Target Price
- XCUR N/A
- MRSN $33.00
- AVG Volume (30 Days)
- XCUR 30.7K
- MRSN 41.5K
- Earning Date
- XCUR 11-13-2025
- MRSN 11-12-2025
- Dividend Yield
- XCUR N/A
- MRSN N/A
- EPS Growth
- XCUR N/A
- MRSN N/A
- EPS
- XCUR N/A
- MRSN N/A
- Revenue
- XCUR N/A
- MRSN $34,769,000.00
- Revenue This Year
- XCUR N/A
- MRSN N/A
- Revenue Next Year
- XCUR N/A
- MRSN N/A
- P/E Ratio
- XCUR N/A
- MRSN N/A
- Revenue Growth
- XCUR N/A
- MRSN 16.14
- 52 Week Low
- XCUR $2.15
- MRSN $5.21
- 52 Week High
- XCUR $36.00
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- XCUR 44.40
- MRSN 61.29
- Support Level
- XCUR $4.12
- MRSN $7.63
- Resistance Level
- XCUR $4.57
- MRSN $8.35
- Average True Range (ATR)
- XCUR 0.34
- MRSN 0.39
- MACD
- XCUR 0.15
- MRSN 0.01
- Stochastic Oscillator
- XCUR 70.56
- MRSN 72.97
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.